Royalty Pharma Plc (RPRX)vsRevolution Medicines Inc (RVMD)
RPRX
Royalty Pharma Plc
$58.52
+0.14%
HEALTHCARE · Cap: $33.75B
RVMD
Revolution Medicines Inc
$192.86
+0.05%
HEALTHCARE · Cap: $41.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 341679% more annual revenue ($2.54B vs $742,000). RPRX leads profitability with a 32.0% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 57/100 (C).
RPRX
Buy57
out of 100
Grade: C
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-58.1%
Fair Value
$36.94
Current Price
$58.52
$21.58 premium
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Earnings declined 46.3%
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Debt/Equity, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RPRX profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
RPRX generates stronger free cash flow (686M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (57/100 vs 24/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?